Trending...
- Memelinked Social Media powered by cryptocurrency launching July 2026 - 260
- Transcure Responds to CMS Removal of 285 Inpatient-Only Procedures - 133
- JiT Home Buyers Strengthens Multi-State Presence as Demand for Flexible Home Selling Solutions Grows - 124
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- Paws In Recovery Named As One of the Top 5 Sober Living Homes in California
- New Compositions for Wind Band
- For True Confessions Day:Confessions told from Video Tombstones and a book called "Cemetery of Lies"
- Snell & Wilmer Welcomes Associate Anjel Bonilla to the Los Angeles Office
- SEEAG's Free "Farm Day Every Day" At Tutti Frutti Farms – March 28 in Lompoc
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor, Senate, Assembly commit to protecting elections from Trump's federal overreach
- FREE MONEY FOR COLLEGE: New effort connects California community college students with available CalKIDS scholarships
- Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
- Orange County's Warm Homes Attract Unwelcome Guests as Rodents Escape Cold
- California sues Trump over his unlawful use of tariffs — again
- Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
- HeapHero Shares Java Heap Sizing Best Practices: Choosing the Right -Xms and -Xmx Parameters
- JiT Home Buyers Discusses Growing Challenges of Vacant Homes Across U.S. Housing Markets
- Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
- Beau Jest at North Coast Repertory Theatre
- Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
- $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
- Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
- ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
- California: Governor Newsom and Acting Governor Kounalakis honor fallen Chief Warrant Officer Three Robert M. Marzan
- Memelinked Social Media powered by cryptocurrency launching July 2026
- Ventura College Foundation Honors 15 "Pirates of Distinction," Launches "Invest in Success"
- City of Long Beach Announces Departure of Director of Technology and Innovation Department
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Alexander Rossi and Mayor Bob Foster to be Inducted into 20th Anniversary Long Beach Motorsports Walk of Fame